Status:

COMPLETED

Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer

Lead Sponsor:

GERCOR - Multidisciplinary Oncology Cooperative Group

Conditions:

Colorectal Cancer

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from...

Detailed Description

OBJECTIVES: Primary * Determine the response rate in patients with recurrent metastatic colorectal cancer treated with neoadjuvant oxaliplatin, fluorouracil, and leucovorin calcium followed by radio...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed adenocarcinoma of the colon or rectum
  • Metastatic disease isolated to the following lymph nodes:
  • Aortic
  • Interaortic
  • Celiomesenteric
  • Retroperitoneal, including the following sites:
  • Peri-uretal
  • Liver
  • Iliac
  • Clavicle
  • Mediastinum
  • Inguinal
  • Cervical
  • Incompletely resected disease
  • Recurrent disease, defined by 1 of the following criteria:
  • Progression occurred within 6 months after prior oxaliplatin or after the patient received no prior oxaliplatin
  • Progressive disease after cisplatin or fluorouracil
  • Must be able to be encompassed in radiation field
  • PATIENT CHARACTERISTICS:
  • ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%
  • Life expectancy more than 12 weeks
  • Absolute neutrophil count ≥ 1,500/mm\^3
  • Platelet count ≥ 100,000 /mm\^3
  • Alkaline phosphatase ≤ 5 times normal
  • Bilirubin ≤ 2 times normal
  • Creatinine \< 2 times normal or creatinine clearance ≥ 40 mL/min
  • No peripheral neuropathy \> grade 1
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No weight loss \> 15% since diagnosis of recurrent disease
  • No uncontrolled heart disease
  • No angina
  • No symptomatic disease of the inferior artery
  • No psychological, familial, sociological, or geographical condition that would preclude study treatment or compliance
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • No prior chemotherapy or radiotherapy
  • No concurrent corticosteroids

Exclusion

    Key Trial Info

    Start Date :

    August 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    39 Patients enrolled

    Trial Details

    Trial ID

    NCT00268333

    Start Date

    August 1 2005

    Last Update

    February 9 2009

    Active Locations (9)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (9 locations)

    1

    Institut Sainte Catherine

    Avignon, France, 84082

    2

    Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz

    Besançon, France, 25030

    3

    Hopital Drevon

    Dijon, France, 21000

    4

    Hopital Robert Boulin

    Libourne, France, 33500